整理 | GLP1减重宝典内容团队 2025年10月31日，乐普医疗发布公告，子公司民为生物将GLP-1/GIP/FGF21新药MWN105的大中华区外全球权益授权给Sidera Bio。 根据协议，民为生物将受到3500万美元预付款及近期里程碑金额，以及获取Sidera Bio公司9.99%的股权。民为生物还将收到不超过 10.1亿美元里程碑金额，以及梯度比例的销售分成。民为生物将与Sidera Bio设立联合管理委员会，协调MWN105的全球开发化。 2021年民为生物完成近亿元首轮融资，民和资本投资；2023年乐普医疗以近4亿元控股民为生物。2025年汉康资本（A轮）和腾讯投资 （A+轮）先后入股民为生物。目前乐普医疗持有民为生物约54.23%股权。 本协议的签署有助于推动GLP-1多靶点药物的全球布局，这类药物因其在糖尿病、肥胖症及代谢性疾病领域的突破性潜力，正成为全球 创新药研发的重要方向。 通过BD合作拓展海外市场，公司将为全球患者提供新的治疗选择，同时进一步提升公司的品牌影响力和国际 竞争力。公司坚持自主研发与开放合作并重，依托国际合作加速GLP-1多靶点药物的临床转化和市场覆盖，深度融入全球药 ...

整理 | GLP1减重宝典内容团队 STEP 5中为STEP系列研究中观察时间最长的，为期108周，该研究表明司美格鲁肽2.4mg可以用于长期体重管理。 肥胖患者在寻求医疗帮助之前平均尝试减肥7次。然而，一旦减肥成功，体重往往会反弹，这就是为什么找到帮助肥胖患者减肥并保持体重的方 法至关重要的原因，STEP 5 临床试验的结果表明，肥胖成年人在服用 Wegovy 时能够减肥，并在两年内保持减肥效果，这可以帮助更好地治 疗和管理肥胖这种慢性疾病。 对于目前的肥胖症治疗，往往会看到治疗的减肥效果随着时间的推移而减弱，研究者着手研究这是否也适用于 2.4 毫克司美格鲁肽。非常鼓舞 的是，即使在使用 2.4 毫克司美格鲁肽治疗两年后，仍然看到 15% 的显著和持续的体重减轻。对于许多人来说，长期保持已实现的体重减轻与 一开始就实现体重减轻一样具有挑战性。 ▍代谢健康、心血管健康的改善：全方位提升 STEP 5 是一项 3b 期随机、双盲、安慰剂对照试验，研究了 2.4 毫克司美格鲁肽作为生活方式干预（每日 500 千卡饮食加上每周 150 分钟体力 活动）的辅助手段对 304 名肥胖且无 2 型糖尿病的成年人持续减重 ...

以下文章来源于内分泌早知道 ，作者关注内分泌的 内分泌早知道 . 深度分享内分泌用药经验、病例剖析、指南专业解读并紧跟国内外内分泌领域前沿进展，「每医健」旗下内容平台。 2024年10月31日，国际顶级期刊《科学》发表了一项颠覆性研究，揭示了婴幼儿饮食中隐藏的健康危机。这项由南加州大学领衔，联 合兰德智库、麦吉尔大学等四所顶尖机构开展的长期追踪研究指出：人生前1000天（孕期至2周岁）的饮食含糖量，直接决定成年后的 代谢健康！ 研究团队发现：过早接触添加糖的婴幼儿，成年后罹患2型糖尿病和高血压的风险呈爆发式增长。更令人震惊的是，只要在婴幼儿期严 格控制添加糖摄入，就能有效阻断这种"代谢记忆"效应，显著降低未来慢性病风险。 历史数据揭示惊人规律 研究团队利用 英国生物银行（UK Bi obank） 的50万份遗传与医疗数据，对比了1 951- 1956年出生的60,1 83名参与者的健康状况。其 中： - "糖限制"组 （19 51 - 1954年出生，母亲孕期糖摄入较低） - " 非限制"组 （1954- 1956年出生，母亲孕期糖摄入较高） 结果显示： ✅ 糖限制组 的后代： ▍关键发现：生命早期糖摄入影响 ...

以下文章来源于肥胖世界ObesityWorld ，作者肥胖世界 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 生物制剂(尤其是重组蛋白)已成为现代医学的核心支柱。虽然这类药物在多种疾病治疗中展现出色疗效，但其短暂的体内半衰期始终是一大掣 肘，而将精准工程化的细胞作为药物递送平台或许能彻底解决这一难题。 慢性疾病因其渐进性且往往不可逆转的特性，使得蛋白类药物通常需要长期(甚至终身)反复注射，才能维持稳定治疗效果。以风靡全球的司美 格鲁肽和替尔泊肽等GLP-1类药物为例，它们虽然重塑了糖尿病和肥胖治疗格局，但作为多肽类生物制剂，仍需每周注射，且必须长期坚持才 能保持效果，一旦停药，减掉的体重会迅速反弹。 近年来，以CAR-T细胞为代表的细胞药物在血液肿瘤和自身免疫性疾病等相对罕见病症中展现出"治愈级"效果。不同于传统药物，CAR-T细 胞是一种"活体"药物，能在患者体内自我复制和长期生存，从而有望实现"一次治疗、长期有效"的理想目标。 2024年3月，彭敏团队在《实验医 ...

以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 节食和运动减肥成功率仅1%！ 全球范围内，儿童和青少年肥胖增长速度将快于超重增长，且2022-2030年间形势将尤为严峻。男孩受影响尤为突出，预计2050年5-14岁男 性肥胖率（16.5%）将高于超重率（12.9%）。北非、中东、拉美和加勒比地区预计将成为全球青少年肥胖"重灾区"，2050年这两地区的青少 年肥胖患者将占全球三分之一（1.3亿人），带来巨大健康、经济和社会负担。同时，预计到2050年，全球近四分之一的肥胖成年人将年满65 岁及以上，这将给本就压力巨大的医疗体系带来更大挑战，特别是资源有限的国家。 研究团队指出， 这场全球性的超重和肥胖流行是一场社会悲剧和重大公共卫生失败。 各国政府和公共卫生部门可根据本报告对各国不同阶 段、速度和体重变化趋势的估算，锁定最需干预和治疗的高风险人群，以及以预防为主的超重人群，制定更有针对性的应对策略。 《柳叶 ...

以下文章来源于内分泌早知道 ，作者关注内分泌的 内分泌早知道 . 深度分享内分泌用药经验、病例剖析、指南专业解读并紧跟国内外内分泌领域前沿进展，「每医健」旗下内容平台。 现代生活让人造光源无处不在，从清晨睁眼查看手机消息到深夜刷剧玩游戏，我们的眼睛几乎全天暴露在各种电子设备发出的光线中。 这种生活方式正在悄然改变人类的昼夜节律，最新研究揭示了一个令人担忧的事实：夜间光照可能成为2型糖尿病的隐形推手。 《柳叶刀》子刊近期发表的一项重磅研究通过对847 90名英国生物库参与者长达7.9年的追踪调查， 结合1300万小时的光传感器数据， 首次系统揭示了夜间光照强度与糖尿病发病率的剂量反应关系 。研究显示，在排除4085例基线糖尿病患者后，随访期间共发现1 997例 新发2型糖尿病病例，相当于每1000人年2.9 8例的发病率。最令人震惊的是，与低光照暴露组相比，夜间暴露于高强度人造光的人群患 糖尿病风险飙升67%，这一数字远超既往研究关于肥胖风险的预测值。 这项研究不仅证实了夜间光照与代谢紊乱的强关联，更通过精确的光照分布时间测量，建立了光照强度与疾病风险的正相关曲线。科学 家指出，人造光源对褪黑激素分泌的干扰可能 ...

整理 | GLP1减重宝典内容团队 「GLP-1俱乐部」覆盖数百位专业人士，构建了围绕GLP-1产业链上下游、覆盖多个板块的专家库，成为了业内顶尖专业人士获取行业真知灼见的首要选择。加入 专家库请添加下方「运营负责人」微信，并提供名片和必要的个人信息。 2025年10月30日，歌礼制药有限公司(香港联交所代码：1672，简称"歌礼")宣布，已选定一款有望成为同类最佳每月一次皮下注射胰淀 素(amylin)受体激动剂ASC36作为临床开发候选药物。歌礼预计将于2026年第二季度向美国食品药品监督管理局(FDA)递交ASC36治疗 肥胖症的新药临床试验申请(IND)。 ASC36是利用歌礼基于结构的AI辅助药物发现(Artificial Intelligence-Assisted Structure-Based Drug Discovery，AISBDD)和超长效药 物开发平台(Ultra-Long-Acting Platform，ULAP)技术自主研发的胰淀素受体激动剂多肽。经设计优化的ASC36实现了更长的表观半衰 期(以血药浓度降至Cmax的50%所需时间计)及更高的每毫克多肽生物利用度，从而支持每月一次皮 ...

Core Insights - Eli Lilly reported Q3 2025 revenue of $17.601 billion, a 54% year-over-year increase, with total revenue for the first nine months reaching $45.887 billion, up 46% [2] - The company's revenue distribution shows significant growth across regions, with the U.S. market contributing $30.604 billion (+43%), Europe $8.461 billion (+89%), Japan $1.478 billion (+18%), China $1.477 billion (+20%), and other markets $3.867 billion (+21%) [2] Revenue Breakdown by Therapeutic Area - Eli Lilly's four main therapeutic areas generated revenues of $33.729 billion for cardiovascular and metabolic health, $6.769 billion for oncology, $3.706 billion for immunology, and $0.932 billion for neurology [4] - The primary revenue drivers for Eli Lilly's pharmaceutical business were Mounjaro and Zepbound, generating $24.837 billion (+125%) and $4.118 billion (+10%) respectively in the first three quarters [4] - Mounjaro and Zepbound sales reached $10.1 billion in Q3 and are projected to exceed $35 billion for the full year [4] Market Position and Competition - Eli Lilly's GLP-1 market share in the U.S. has surpassed that of Novo Nordisk, with prescription volume shares of 57.9% versus 41.7% in Q3 [4] - Keytruda, another leading drug, generated $23.3 billion in sales during the first three quarters, highlighting the competitive landscape [4] Research and Development Progress - Eli Lilly achieved significant milestones in R&D, completing six Phase III studies for the small molecule GLP-1R agonist Orforglipron and reaching primary endpoints for Mounjaro in treating type 2 diabetes in children and adolescents [6] - Upcoming developments include the submission of Orforglipron for market approval and the completion of a Phase III study for Retatrutide targeting knee osteoarthritis pain [6] - The company also terminated two clinical projects in Q3, focusing on pain treatment and metastatic breast cancer [6]

Core Viewpoint - The article emphasizes the potential health risks associated with the consumption of processed foods containing various food additives, highlighting a significant correlation between these additives and chronic diseases such as type 2 diabetes [4][6][10]. Group 1: Health Risks of Food Additives - Processed foods often contain food additives like modified starch, pectin, and natural colorants, which enhance taste and appearance but may pose health risks [4]. - A study published in PLOS Medicine indicates that long-term consumption of food additives in combination may be linked to the onset of chronic diseases [4][6]. - The complex biological effects of food additives, even those deemed safe individually, can lead to unexpected health consequences when consumed together [6][9]. Group 2: Research Findings on Additive Combinations - A large-scale study tracked 108,643 adults over 7.7 years, analyzing 269 common food additives and identifying 75 frequently consumed ones, revealing typical combinations of additives [7]. - The study categorized these additives into five typical combinations, with the most representative being the "processed food framework," which includes thickeners and preservatives commonly found in dairy products and condiments [7]. - Specific combinations of additives, such as emulsifiers and preservatives, are associated with potential metabolic disorders, indicating the need for comprehensive safety assessments [7][10]. Group 3: Diabetes Risk and Additive Interaction - The research found a significant association between certain food additive combinations and the incidence of type 2 diabetes, with 1,131 new cases identified among the study participants [8]. - The first group of additives (including modified starch and emulsifiers) showed an 8% increase in diabetes risk per standard intake, while the second group (mainly artificial sweeteners) had a risk increase of 13% [8]. - The interactions between these additives can amplify inflammatory responses or counteract toxic effects, complicating the assessment of their health impacts [9]. Group 4: Implications for Food Safety Regulations - The findings suggest that current food safety assessments, which focus on individual additives, are inadequate and should incorporate evaluations of common additive combinations [10]. - The article calls for a new regulatory framework that considers the potential health impacts of frequently co-occurring additives, particularly in ultra-processed foods [10]. - Consumers are encouraged to be more vigilant about reading ingredient labels, as the presence of multiple additives may significantly affect metabolic health [10].

Core Viewpoint - Semaglutide can improve health and slow the aging process, significantly reducing the risk of major adverse cardiovascular events (MACE) in overweight or obese patients with cardiovascular disease but without diabetes [2][4][5]. Group 1: Introduction and Background - GLP-1 receptor agonists (GLP-1RAs) were initially used for blood glucose control in type 2 diabetes, showing weight loss and cardiovascular risk improvement in non-diabetic populations [4][5]. - Obesity is a major risk factor for cardiovascular morbidity and mortality, affecting through hemodynamic, metabolic, and inflammatory pathways [4]. - Prior cardiovascular outcome trials of GLP-1RAs were primarily conducted in type 2 diabetes patients, complicating the interpretation of cardiovascular benefits due to diabetes-related effects [5]. Group 2: Study Design and Methods - The SELECT trial recruited patients aged at least 45 years with a BMI ≥ 27 kg/m², randomly assigning them to receive either 2.4 mg semaglutide weekly or a placebo [7][13]. - The primary endpoint was the time to the first occurrence of MACE, including cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke [7][8]. Group 3: Results - In 17,604 patients, semaglutide significantly reduced the incidence of MACE across all baseline weight and waist circumference categories [9]. - A linear trend analysis indicated that a 5 kg weight reduction was associated with a 4% average decrease in MACE risk (HR 0.96 [95% CI 0.94–0.99]; p=0.001) [9]. - Waist circumference reduction was correlated with decreased MACE risk, with approximately 33% of the observed MACE benefit mediated through waist circumference changes [9][10]. Group 4: New Insights and Implications - The cardiovascular protective effects of semaglutide are independent of baseline fat measurements and weight changes, suggesting mechanisms beyond fat reduction [10][11]. - The findings indicate that semaglutide and other GLP-1RAs should be redefined as disease-modifying treatments rather than solely for blood glucose control or weight loss [11]. - Prescribing restrictions based on BMI thresholds or weight loss targets may not be applicable to overweight or obese patients, as they may benefit regardless of weight loss response [11].